IP Library Granted Patent US 9,765,327
Granted Patent B2
US 9,765,327 · App. 15/183,191 · Granted Sep 19, 2017

Induction of hemogenic endothelium from pluripotent stem cells

Inventors: Igor Slukvin (Verona, WI); Irina Elcheva (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation
C12N15/11C12N5/0647C12N15/00C12N15/66C12N2501/60C12N2501/998C12N2506/02C12N2506/45C12N2510/00C12N2740/16043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,765,327
App. No.
15/183,191
Granted
Sep 19, 2017
Kind
B2
Abstract

Described herein are methods and related compositions for inducing differentiation of human pluripotent stem cells (hPSCs) into hemogenic endothelium with pan-myeloid potential or restricted potential, by forced expression in the hPSCs of a combination of transcription factors as described herein.

Claims (31)

1. A kit for hemogenic reprogramming, comprising:

one or more recombinant expression viruses comprising a nucleic acid encoding an ETV2 or ERG protein, and a GATA1 protein.

2. The kit of claim 1 , wherein the ETV2, ERG, or GATA1 sequence are from human, mouse, or rat.

3. A kit for hemogenic reprogramming, comprising:

one or more isolated modified mRNAs comprising an open reading frame for ETV2 or ERG, and GATA1, wherein the modified mRNA comprises:

a 5′ synthetic cap;

modified nucleotides, wherein the modified nucleotides comprise a member selected form the group consisting of pseudo-uridine and 5-methyl-cytosine; and

a 3′ poly-A tail.

4. The kit of claim 3 , wherein the 5′ synthetic cap is methylated.

5. A kit for hemogenic reprogramming, comprising:

one or more isolated modified mRNAs comprising an open reading frame from ETV2 or ERG, and GATA1, wherein the modified mRNA comprises:

a 5′ synthetic cap;

modified nucleotides; and

a poly-A tail, wherein the modified mRNA comprises 3′-O-Me-m7G(5′)pp(5′)G.

6. The kit of claim 1 , wherein the ETV2 protein comprises SEQ ID NO:1.

7. The kit of claim 1 , wherein the ERG protein comprises SEQ ID NO:3.

8. The kit of claim 1 , wherein the GATA protein comprises SEQ ID NO:2.

9. A kit for hemogenic reprogramming, comprising:

one or more double stranded DNA expression vectors comprising a heterologous nucleic acid sequence encoding an ETV2 or ERG protein and a GATA1 protein.

10. The kit of claim 9 , wherein the ETV2, ERG, or GATA1 sequence are from human, mouse, or rat.

11. The kit of claim 9 , wherein the ETV2 protein comprises SEQ ID NO:1.

12. The kit of claim 9 , wherein the ERG protein comprises SEQ ID NO:3.

13. The kit of claim 9 , wherein the GATA protein comprises SEQ ID NO:2.

14. The kit of claim 1 , wherein the ETV2, ERG, or GATA1 sequence are from human, mouse, or rat.

15. The kit of claim 3 , wherein the ETV2 protein comprises SEQ ID NO:1.

16. The kit of claim 3 , wherein the ERG protein comprises SEQ ID NO:3.

17. The kit of claim 3 , wherein the GATA protein comprises SEQ ID NO:2.

18. The kit of claim 5 , wherein the ETV2, ERG, or GATA1 sequence are from human, mouse, or rat.

19. The kit of claim 5 , wherein the ETV2 protein comprises SEQ ID NO:1.

20. The kit of claim 5 , wherein the ERG protein comprises SEQ ID NO:3.

21. The kit of claim 5 , wherein the GATA protein comprises SEQ ID NO:2.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 16, 2018
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046172/0838 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2016
From: SLUKVIN, IGOR; ELCHEVA, IRINA
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 039103/0968 →
Continuity (3)
Division 14058959 · Oct 21, 2013
Provisional Application 61716875 · Oct 22, 2012
Related Publication 20160355786A1 · Dec 8, 2016